

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/21, 38/19, 38/18 // (A61K 38/21, 31:70)		A1	(11) International Publication Number: WO 97/16204
			(43) International Publication Date: 9 May 1997 (09.05.97)
(21) International Application Number: PCT/US96/17085			(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 31 October 1996 (31.10.96)			
(30) Priority Data: 60/006,130 2 November 1995 (02.11.95) US			
(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			
(72) Inventors: CUTLER, David, L.; 4 Windsor Way, Morristown, NJ 07960 (US). AFFRIME, Melton, B.; 2 Horseshoe Drive, Flemington, NJ 08822 (US).			
(74) Agents: FOULKE, Cynthia, L. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CONTINUOUS LOW-DOSE CYTOKINE INFUSION THERAPY			
(57) Abstract <p>A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein the undesirable side effects normally associated with cytokine administration are diminished or eliminated. The method comprises continuously administering a low dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine. In a preferred embodiment of the invention, chronic hepatitis C is treated by administering a low dose amount of interferon.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

CONTINUOUS LOW-DOSE CYTOKINE INFUSION THERAPY

Field Of The Invention

10 The invention relates to a method of treating medical conditions, in particular viral infections, that are susceptible to treatment with a cytokine comprising the continuous administration of a low dose of the cytokine. In a preferred embodiment of the invention, continuous low-dose infusion of interferon is used to treat chronic hepatitis C.

15

Background Of The Invention

Interferons are a family of naturally occurring small proteins and glycoproteins produced and secreted by most nucleated cells in response to viral infection as well as other antigenic stimuli. Interferons render cells
20 resistant to viral infection and exhibit a wide variety of actions on cells. They exert their cellular activities by binding to specific membrane receptors on the cell surface. Once bound to the cell membrane, interferons initiate a complex sequence of intracellular events. *In vitro* studies demonstrated that these include the induction of certain enzymes, suppression of cell proliferation,
25 immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells.

Nonimmun interf rons, which include both alpha and beta interferons, are known to suppress human immunod ficiency virus (HIV) in both

acutely and chronically infected cells. Poli and Fauci, 1992, *AIDS Research and Human Retroviruses* 8(2):191-197. Interferons, in particular, alpha interferons, have received considerable attention as therapeutic agents in the treatment of hepatitis C virus (HCV)-related disease due to their antiviral activity.

- 5 Hoofnagle *et al.*, in: *Viral Hepatitis 1981 International Symposium*, 1982, Philadelphia, Franklin Institute Press; Hoofnagle *et al.*, 1986, *New Eng. J. Med.* 315:1575-1578; Thomson, 1987, *Lancet* 1:539-541 Kiyosawa *et al.*, 1983, in: Zuckerman, ed., *Viral Hepatitis and Liver Disease*, Allen K. Liss, New York pp. 895-897; Hoofnagle *et al.*, 1985, *Sem. Liv. Dis.*, 1985, 9:259-263.

- 10 Chronic hepatitis C is an insidious and slowly progressive disease having a significant impact on the quality of life. Despite improvement in the quality of the blood-donor pool and the recent implementation of testing of donated blood for HCV, the estimated incidence of acute infection among persons receiving transfusions is 5 to 10%. Alter *et al.*, in: Zuckerman, ed., *Viral*
15 *Hepatitis and Liver Disease*, Allen K. Liss, New York, 1988, pp. 537-542. Thus, of the approximately 3 million persons who receive transfusions in the United States each year, acute hepatitis C will develop in about 150,000. While many patients who contract hepatitis C will have subclinical or mild disease, approximately 50% will progress to a chronic disease state characterized by
20 fluctuating serum transaminase abnormalities and inflammatory lesions on liver biopsy. It is estimated that cirrhosis will develop in up to about 20% of this group. Koretz *et al.*, 1985, *Gastroenterology* 88:1251-1254.

- Interferons are known to affect a variety of cellular functions, including DNA replication and RNA and protein synthesis, in both normal and
25 abnormal cells. Thus, cytotoxic effects of interferon are not restricted to tumor or virus infected cells but are also manifested in normal, healthy cells as well. As a result, undesirable side effects arise during interferon therapy, particularly when high doses are required. Administration of interferon can lead to myelosuppression resulting in reduced red blood cell, white blood cell and

platelet levels. Higher doses of interferon commonly give rise to flu-like symptoms (e.g., fever, fatigue, headaches and chills), gastrointestinal disorders (e.g., anorexia, nausea and diarrhea), dizziness and coughing.

Interferon alpha-2b has been shown to be safe and effective when administered subcutaneously at a dose of 3×10^6 international units (IU) three times a week for 24 weeks for the treatment of chronic hepatitis C. Causse *et al.*, 1991, *Gastroenterology* 101:497-502; Davis *et al.*, 1989, *New Eng. J. Med.* 321:1501-1506; Marcellin *et al.*, 1991, *Hepatology*, 13(3):393-393. This amount and duration alleviates symptoms of hepatitis C and biochemical or histological evidence of ongoing inflammation of the liver in some patients but it also causes undesirable side effects, e.g., flu-like symptoms. While Carreno *et al.* (*Journal of Medical Virology*, 1992, 37:215-219) reported treatment of patients with chronic hepatitis C with a daily dose of 9×10^6 IU Roferon® A administered for 28 days by continuous subcutaneous infusion to patients with chronic hepatitis C, all twelve of the patients treated had flu-like symptoms and fever. During the first week of treatment 8 patients experienced headache and arthralgias. Eight patients had some hair loss, 9 patients suffered weight loss of between 2-5 kg, and 11 patients had decreases in platelet and leukocyte counts. While significant decreases in serum ALT levels were reported, HCV RNA remained positive during the treatment period.

Continuous infusion of interferon has also been used in the treatment of cancer patients. See Dorr *et al.*, 1988, *Journal of Interferon Research* 8:717-725, which reports continuous 28-day subcutaneous infusion of Roferon®A at doses of from 0.7×10^6 to 5.0×10^6 IU/m² body surface area and Ludwig *et al.*, 1986, *Proc. Am. Soc. Clin. Oncol.* 5:234, Abstr. 915, which reports continuous subcutaneous infusion of $3-18 \times 10^6$ IU/day of Roferon®A for periods of more than 3 months.

Undesirable side effects, such as those accompanying interferon therapy, also occur in treatment protocols employing other cytokines. Such side

effects frequently limit the therapeutic usefulness of such agents. Thus, a need exists to reduce or eliminate the undesirable side effects of cytokine therapy without diminishing the therapeutic benefits of such therapy.

5 Summary Of The Invention

The present invention fulfills this need by providing a method of treating conditions that are susceptible of treatment with a cytokine, wherein undesirable side effects normally associated with such treatments are significantly diminished or eliminated entirely.

10 An object of the invention is to provide a method of treating a mammal afflicted with a condition that is susceptible to treatment with a cytokine comprising administering to a mammal in need of cytokine therapy a low-dosage amount of a cytokine by continuous infusion of the cytokine.

Another object of the invention is to treat viral infections
15 comprising continuously administering a low dosage amount of a cytokine to a mammalian host infected with a virus susceptible to treatment by the cytokine.

Yet another object of the invention is directed to a method of treating chronic hepatitis C virus infection comprising continuously administering to a mammalian host infected with hepatitis C virus a low dosage
20 amount of interferon, preferably alpha interferon, more preferably interferon alpha-2b.

Detailed Description Of The Invention

All references cited herein are incorporated in their entirety by
25 reference.

The invention is directed to a method of treating conditions that are susceptible of treatment with a cytokine. It has been unexpectedly discovered that continuous administration of low doses of cytokines over a prolonged period of time provides effective therapeutic benefits, while significantly

diminishing the undesirable side effects normally associated with conventionally practiced cytokine treatment regimes.

Conditions that can be treated in accordance with the present invention are generally those that are susceptible to cytokine treatment.

5 Cytokine-susceptible conditions include conditions which would respond positively or favorably as these terms are known in the medical arts to cytokine-based therapy. For purposes of the invention, conditions that can be treated with cytokine therapy include those conditions in which treatment with a cytokine shows some efficacy, but which may not be treatable with the cytokine
10 because the negative side effects outweigh the benefits of the treatment. For example, side effects accompanying alpha interferon therapy have virtually ruled out treatment of Epstein Barr virus using alpha interferon. Practice of the invention results in substantially reduced or eliminated side effects as compared to conventional interferon treatment.

15 Cytokines which can be used to practice the invention include but are not limited to interferons, granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF), erythropoietin, thrombopoietin and interleukins. In addition, other therapeutic agents, such as antibodies and fragments thereof (e.g., Fab
20 fragments), soluble cytokine receptors and cytokine receptor antagonists can advantageously be administered in accordance with the practice of the invention.

Cytokines can be used alone or in combination with other cytokines and/or therapeutic agents. For example, interferon can be used alone
25 or in combination with AZT in the treatment of HIV/AIDS or in combination with ribivirin in the treatment of HCV.

While the invention will hereinafter be described in terms of the use of interferon, it is to be understood that the administration of other cytokines,

alone or in combination with one or more other therapeutic agents, is encompassed by the invention.

The term "interferon" as used herein means the family of highly homologous species-specific proteins that inhibit viral replication and cellular proliferation and modulate immune response. Human interferons are grouped into three classes based on their cellular origin and antigenicity: α -interferon (leukocytes), β -interferon (fibroblasts) and γ -interferon (T cells). Recombinant forms of each group have been developed and are commercially available. Subtypes in each group are based on antigenic/structural characteristics. At least 14 α -interferons (grouped into subtypes A through H) having distinct amino acid sequences have been identified by isolating and sequencing DNA encoding these peptides. Both naturally occurring and recombinant α - β - and γ -interferons, including consensus interferon, may be used in the practice of the invention.

The purification of interferon from human leukocytes isolated from the buffy coat fraction of whole blood is described in U.S. Patent No. 4,503,035. Human leukocyte interferon prepared in this manner contains a mixture of different human leukocyte interferon amino acid sequences. Purified natural human α -interferons and mixtures thereof which may be used in the practice of the invention include but are not limited to Sumiferon[®] interferon alfa-n1 available from Sumitomo, Japan, Wellferon[®] interferon alfa-n1 (Ins) available from Glaxo-Wellcome Ltd., London, Great Britain, and Alferon[®] interferon alfa-n3 available from the Purdue Frederick Co., Norwalk, CT.

The advent of recombinant DNA technology applied to interferon production has permitted several human interferons to be successfully synthesized, thereby enabling the large-scale fermentation, production, isolation, and purification of various interferons to homogeneity. Recombinantly produced interferon retains its *in vitro* and *in vivo* antiviral and immunomodulatory activities. It is also understood that

the recombinant techniques could also include a glycosylation site for addition of a carbohydrate moiety on the recombinantly-derived polypeptide.

The construction of recombinant DNA plasmids containing sequences encoding at least part of human leukocyte interferon and the expression in *E. coli* of a polypeptide having immunological or biological activity of human leukocyte interferon is disclosed in U.S. Patent No. 4,530,901. The construction of hybrid α -interferon genes containing combinations of different subtype sequences (e.g., A and D, A and B, A and F) is disclosed in U.S. Patent Nos. 4,414,150, 4,456,748 and 4,678,751. Typical suitable recombinant α -interferons which may be used in the practice of the invention include but are not limited to interferon alfa-2b such as Intron[®] A available from Schering Corporation, Kenilworth, N.J., interferon alfa-2a such as Roferon[®] A available from Hoffmann-La Roche, Nutley, N.J. and interferon alfa-2c such as Berofer[®] available from Boehringer Ingelheim Pharmaceutical, Inc., Ridgefield, CT. U.S. Patent Nos. 4,695,623 and 4,897,471 disclose human leukocyte interferon polypeptides, referred to as consensus interferon, which have amino acid sequences which include common or predominant amino acids found in each position among naturally-occurring alpha interferon subtype polypeptides. Consensus interferon which may also be used in the practice of the invention is available from Amgen, Inc., Newbury Park, CA.

Suitable β -interferons which may be used to practice the invention include but are not limited to Betaseron[®] interferon beta-1b, a synthetic mutein having a serine substituted for the cysteine residue at position 171 of the native molecule, available from Berlex Laboratories, Richmond, CA. Suitable γ -interferons which may be used to practice the invention include but are not limited to Actimmune[®] recombinant interferon gamma-1b available from Genentech, South San Francisco, CA.

Exemplary conditions which can be treated with interferon include but are not limited to cell proliferation disorders, in particular cancer (e.g., hairy

cell leukemia, Kaposi's sarcoma, chronic myelogenous leukemia, multiple myeloma, basal cell carcinoma and malignant melanoma, ovarian cancer, cutaneous T cell lymphoma), and viral infections. Without limitation, treatment with interferon may be used to treat conditions which would benefit from

5 inhibiting the replication of interferon-sensitive viruses. Viral infections which may be treated in accordance with the invention include hepatitis A, hepatitis B, hepatitis C, other non-A/non-B hepatitis, herpes virus (Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex, human herpes virus type 6 (HHV-6)), papilloma, poxvirus, picornavirus, adenovirus, rhinovirus, human T

10 lymphotropic virus-type 1 and 2 (HTLV-1/-2), human rotavirus, rabies, retroviruses including human immunodeficiency virus (HIV), encephalitis and respiratory viral infections. The method of the invention can also be used to modify various immune responses.

Two variants of α -interferon are currently approved in the United

15 States and other countries for the treatment of hairy cell leukemia, venereal warts, Kaposi's Sarcoma, and chronic non-A/non-B hepatitis: interferon alfa-2b, marketed under the trade name INTRON[®] A (Schering Corporation, Kenilworth NJ) and interferon alfa-2a, marketed under the trade name Roferon[®] A (Hoffmann-La Roche, Nutley, NJ). Since interferon alpha-2b, among all

20 interferons, has the broadest approval throughout the world for treating chronic hepatitis C infection, it is most preferred for use in the treatment of chronic hepatitis C in accordance with practice of the invention.

A person suffering from chronic hepatitis C infection may exhibit one or more of the following signs or symptoms: (a) elevated ALT, (b) positive

25 test for anti-HCV antibodies, (c) presence of HCV as demonstrated by a positive test for HCV-RNA, (d) clinical stigmata of chronic liver disease, (e) hepatocellular damage. Such criteria may not only be used to diagnose hepatitis C, but can be used to evaluate a patient's response to drug treatment.

Elvated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are known to occur in uncontrolled hepatitis C, and a complete response to treatment is generally defined as the normalization of these serum enzymes, particularly ALT (Davis *et al.*, 1989, *New Eng. J. Med.* 321:1501-1506). ALT is an enzyme released when liver cells are destroyed and is symptomatic of HCV infection. Interferon causes synthesis of the enzyme 2',5'-oligoadenylate synthetase (2'5'OAS), which in turn, results in the degradation of the viral mRNA. Houghum, 1983, *Clinical Pharmacology* 2:20-28. Increases in serum levels of the 2'5'OAS coincide with decrease in ALT levels.

In order to follow the course of HCV replication in subjects in response to drug treatment, HCV RNA may be measured in serum samples by, for example, a nested polymerase chain reaction assay that uses two sets of primers derived from the NS3 and NS4 non-structural gene regions of the HCV genome. Farci *et al.*, 1991, *New Eng. J. Med.* 325:98-104. Ulrich *et al.*, 1990, *J. Clin. Invest.*, 86:1609-1614.

Histological examination of liver biopsy samples may be used as a second criteria for evaluation. See, e.g., Knodell *et al.*, 1981, *Hepatology* 1:431-435, whose Histological Activity Index (portal inflammation, piecemeal or bridging necrosis, lobular injury and fibrosis) provides a scoring method for disease activity.

In the practice of the invention, a low dose of interferon is continuously administered to a mammal, in particular a human patient, exhibiting one or more of the above signs or symptoms in an amount and for a period of time sufficient to eliminate or at least alleviate one or more of the above-mentioned signs or symptoms.

As used herein, a low dose is an amount which for a given period of time is less than or equal to amounts used in traditional bolus or intermittent therapies over such a time period. The terms "continuous administration" and

"continuous infusion" are used interchangeably herein and mean maintaining a steady state serum level of interferon throughout the course of the treatment period. This can be accomplished by constantly or repeatedly injecting substantially identical amounts of interferon, e.g., at least every hour, 24 hours a day, seven days a week, such that a steady state serum level is achieved for the duration of treatment.

Continuous low dose interferon administration may be by subcutaneous or intravenous injection at appropriate intervals, e.g. at least hourly, for an appropriate period of time in an amount which will facilitate or promote *in vivo* inactivation of hepatitis C virus.

Continuous subcutaneous administration can be accomplished by, for example, a pulsatile electronic syringe driver (Provider Model PA 3000, Pancretec Inc., San Diego CA), a portable syringe pump such as the Graseby model MS 16A (Graseby Medical Ltd., Watford, Herts England), or a constant infusion pump such as the Disetronic Model Panomat C-5. Osmotic pumps, such as that available from Alza, may also be used. Since use of continuous subcutaneous injections allows the patient to be ambulatory, it is preferred over use of continuous intravenous injections.

Formulations which simulate a constant low dose injection, such as but not limited to long-acting cytokine-polymer conjugates and various-sustained release formulations, are also contemplated for use.

Cytokine conjugates can be prepared by coupling a cytokine, such as interferon, to a water-soluble polymer. A non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof. As an alternative to polyalkylene oxide-based polymers, effectively non-antigenic materials such as dextran, polyvinyl pyrrolidones, polyacrylamides, polyvinyl alcohols, carbohydrate-based polymers and the like can be used. Such interferon-polymer conjugates are

described in U.S. Patent No. 4,766,106, U.S. Patent No. 4,917,888, European Patent Application No. 0 236 987, European Patent Application No. 0 510 356 and International Application Publication No. WO 95/13090. Since the polymeric modification sufficiently reduces antigenic responses, the foreign
5 interferon need not be completely autologous. Interferon used to prepare polymer conjugates may be prepared from a mammalian extract, such as human, ruminant or bovine interferon, or recombinantly produced.

Various extended- or sustained-release formulations can be prepared using conventional methods well known in the art.

10 Constant low dose administration may also be accomplished by gene therapy, e.g., by administering an interferon retroviral or other vector so as to produce interferon *in vivo*.

In general, components of interferon compositions can be selected from among those commonly employed with interferons and other
15 antiproliferative or antiviral agents and which are known to those skilled in the art. Conventional pharmaceutical compositions comprising a therapeutically effective amount of interferon together with pharmaceutically acceptable carriers, adjuvants, diluents, preservatives and/or solubilizers may be used in the practice of the invention. Pharmaceutical compositions of interferon include
20 diluents of various buffers (e.g., Tris-HCl, acetate, phosphate) having a range of pH and ionic strength, carriers (e.g., human serum albumin), solubilizers (e.g., tween, polysorbate), and preservatives (e.g., thimerosal, benzyl alcohol). Pharmaceutical composition of interferon are commercially available as injectable solutions and as lyophilized powders which are reconstituted in an
25 appropriate diluent prior to injection.

Duration of treatment is at least 4 weeks, preferably 12 weeks or longer. For treatment of chronic HCV in accordance with the practice of the invention, a total weekly dose of alpha interferon-2b should range from 2 to 10

million IU, more preferable, 5-10 million IU, most preferably 8-10 million IU per week.

While administration or infusion is to be continuous, frequency of injection of the interferon composition will depend on the form of the composition. It will be understood that injection will be less frequent (e.g., once or twice a week) when using sustained release formulations or long-acting polymer conjugates. A single injection may be sufficient when using viral vectors to express the cytokine *in vivo*.

As described above, the course of the disease and its response to drug treatments may be followed by clinical examination and laboratory findings. The effectiveness of the therapy of the invention is determined by the extent to which the previously described signs and symptoms of chronic hepatitis are alleviated and the extent to which the normal side effects of interferon (i.e., flu-like symptoms such as fever, headache, chills, myalgia, fatigue, etc. and central nervous system related symptoms such as depression, paresthesia, impaired concentration, etc.) are eliminated or substantially reduced.

The invention can be illustrated by the following non-limiting example.

Example

Seven human patients with chronic hepatitis C were treated in accordance with the invention.

Human subjects selected for treatment were chosen from anti-HCV antibody positive patients with biopsy documented chronic active hepatitis. Each patient was positive for antibody to hepatitis C virus (anti-HCV) by supplemental assay (Ortho or Abbott) and had previous liver biopsy with features of chronic hepatitis.

Each patient treated in accordance with the invention had previously undergone a 24 week course of INTRON® A administered by subcutaneous injection, 3×10^6 IU three times a week with complete response (defined as normalization of ALT), followed by relapse of chronic hepatitis C (loss of ALT response).

All patients were treated for 12 weeks with a low-dose subcutaneous infusion of INTRON® A. INTRON® A was administered at a concentration of 5×10^6 IU/ml at an infusion rate of 0.012 ml/hr into the subcutaneous tissue of the anterior abdominal wall by continuous subcutaneous infusion using a constant infusion pump (Disetronic Model Panomat C-5). Thus, INTRON® A was continuously administered at a daily rate of 1.4×10^6 IU/day (60×10^3 IU/hr), or approximately 10×10^6 IU/week.

Patients were monitored weekly for clinical symptoms, pharmacodynamics (serum β_2 -microglobulin, 2'5'OAS, serum IFN α -2b concentration) and antiviral response (ALT normalization, disappearance of hepatitis C RNA (HCV-RNA) by immunoassay and polymerase chain reaction).

Therapy was well tolerated. Adverse events were mild and consisted primarily of fatigue. All patients had a 50% or greater decrease in ALT. Four patients had persistent normalization of ALT during therapy. β_2 microglobulin and 2'5'OAS concentrations remained elevated above baseline throughout treatment without indication of down-regulation of response. HCV-RNA by immunoassay became negative in all patients, with a mean time to response of 4 weeks. Mean serum IFN α -2b concentrations were detectable, but were less than the limit of quantification of the assay (10 IU/ml).

This example shows that constant low concentrations of IFN α -2b are effective in normalizing ALT and suppressing HCV replication. No evidence of down-regulation of pharmacodynamic response was observed.

While the results were transient in that the markers return upon cessation of the therapy, longer treatment is expected to result in clinical

improvements based on normal transaminase levels and further treatment to cure (normal liver histology) even on removal of treatment.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

CLAIMS

- 15 -

1. A method of treating a viral infection susceptible to treatment with a cytokine comprising continuously administering a cytokine to a
5 mammal having a viral infection susceptible to treatment with the cytokine, said cytokine being continuously administered in a low dosage amount, said amount being effective to treat the viral infection while reducing or eliminating adverse side effects normally associated with administration of the cytokine.
- 10 2. The method of claim 1 wherein the cytokine is selected from the group consisting of interferons, interleukins, G-CSF, GM-CSF, TNF, erythropoietin and thrombopoietin.
- 15 3. The method of claim 2 wherein the cytokine is interferon.
4. The method of claim 3 wherein the interferon is alpha interferon.
- 20 5. The method of claim 4 wherein the alpha interferon is interferon alpha-2b.
6. The method of claim 1 wherein continuous administration is accomplished by subcutaneous injection of the cytokine.
- 25 7. The method of claim 1 wherein continuous administration is accomplished by injection of a sustained-release formulation of the cytokine.
8. Th method of claim 1 wherein continuous administration is accomplished by injection of a polymer-cytokine conjugate.

- 16 -

9. The method of claim 8 wherein the polymer is polyethylene glycol.

10. The method of claim 1 wherein continuous administration is accomplished by *in vivo* production of the cytokine.

11. The method of claim 6 wherein the cytokine is interferon alpha-2b, said interferon being administered in an amount of from about 2 million IU per week to about 10 million IU per week.

10

12. The method of claim 3 wherein the viral infection is hepatitis.

13. The method of claim 12 wherein the viral infection is chronic hepatitis C.

15

14. The method of claim 13 wherein the interferon is used in combination with ribivirin.

20

15. The method of claim 13 wherein the interferon is used in combination with at least one other cytokine selected from the group consisting of G-CSF, GM-CSF, IL-1, IL-3, IL-6 and erythropoietin.

25

16. The method of claim 1 wherein the viral infection is HIV.

17. The method of claim 16 wherein the cytokine is interferon.

18. The method of claim 16 wherein the cytokine is interleukin-2, interleukin-4, or interleukin-10.

- 17 -

19. The method of claim 13 wherein the mammal is a human and the weekly amount of interferon which is continuously administered is from 2 to 10 million IU.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/17085A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/21 A61K38/19 A61K38/18 //(A61K38/21,31:70)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X Y	EP 0 707 855 A (SCHERING CORPORATION) 24 April 1996 see page 2, column 1, line 32 - line 38; claims see page 2, column 2, line 40 - line 58 see page 3, column 3, line 15 - line 26 ---	1-7, 10-14,19 8,9,15
X Y	WO 94 14474 A (SCHERING CORPORATION) 7 July 1994 see page 3, line 15 - line 29; claims; example 1 see page 7, line 18 - line 29 --- -/--	1-7,10, 11,15-17 8,9,15, 18

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

6 March 1997

Date of mailing of the international search report

17. 03. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 96/17085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 235 906 A (GENENTECH, INC.) 9 September 1987	1-7, 10-12, 16,17 8,9,18
Y	see page 3, line 11 - line 18; claims 1-19; example 9 see page 3, line 52 - line 53 see page 4, line 51 - line 53 see page 5, line 39 - line 48 see page 7, line 17 - line 21 ---	
Y	WO 93 20835 A (SCHERING CORPORATION) 28 October 1993 see page 8, line 30 - line 32; claims ---	15
Y	WO 95 13090 A (ENZON, INC.) 18 May 1995 cited in the application see page 12, line 14 - page 13, line 18; claims 1,6,8 ---	8,9
Y	WO 94 04179 A (SCHERING CORPORATION) 3 March 1994 see page 6, line 2 - line 24; claims ---	18
A	JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, vol. 8, no. 1, 1 January 1995, NWE YORK, N.Y.,US, pages 45-50, XP000645339 D.W. NORTHFELT ET AL.: "CONTINUOUS LOW-DOSE INTERFERON-ALPHA THERAPY FOR HIV-RELATED IMMUNE THROMBOCYTOPENIC PURPURA." see the whole document ---	1-15,19
A	BRITISH MEDICAL JOURNAL, vol. 298, no. 6666, 14 January 1989, LONDON, GB, pages 80-82, XP000645348 M.R. JACYNA ET AL.: "RANDOMISED CONTROLLED TRIAL OF INTERFERON ALPHA (LYMPHOBLASTOID INTERFERON) IN CHRONIC NON-A NON-B HEPATITIS. " see the whole document -----	1-15,19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 17085

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-19
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1 to 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/17085

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 707855 A	24-04-96	AU 5919296 A	29-11-96
		WO 9636351 A	21-11-96
WO 9414474 A	07-07-94	AU 5953494 A	19-07-94
EP 235906 A	09-09-87	US 4828830 A	09-05-89
		AU 598225 B	21-06-90
		AU 6796287 A	30-07-87
		CA 1296252 A	25-02-92
		CN 1023295 B	29-12-93
		DK 169234 B	19-09-94
		JP 2510181 B	26-06-96
		JP 62215535 A	22-09-87
		GB 2194146 A	02-03-88
		IE 59814 B	06-04-94
WO 9320835 A	28-10-93	AU 3945393 A	18-11-93
		CN 1085802 A	27-04-94
		ZA 9302603 A	13-10-93
WO 9513090 A	18-05-95	AU 1179895 A	29-05-95
		EP 0730470 A	11-09-96
WO 9404179 A	03-03-94	AU 5007593 A	15-03-94
		CA 2142862 A	03-03-94
		CN 1086437 A	11-05-94
		CZ 9500380 A	13-12-95
		EP 0656785 A	14-06-95
		FI 950696 A	16-02-95
		HU 72709 A	28-05-96
		JP 7506116 T	06-07-95
		NO 950599 A	17-02-95
		PL 307508 A	29-05-95
		SK 21295 A	08-01-97
		ZA 9306018 A	13-06-94